Logo

DNAStar Lasergene 17.2 Software

Nov 20, 2020

DNAStar has released Lasergene 17.2 software for DNA, RNA, and protein sequencing assembly and analysis. In the latest release, DNAStar has fully integrated the SeqMan NGen application into SeqMan Ultra, greatly improving the workflow for both Sanger and next-generation sequencing analysis.

Users performing sequence assemblies can now go from project setup to finished assembly in one application. For users working with Sanger sequencing data, the new software offers improvements such as the ability to preview and trim trace data prior to assembly; better access to a built-in vector trimming database; and the ability to easily export an image of the assembly for collaboration or publication.

For those doing NGS assembly, the new version includes an updated variant annotation database to enrich the analysis of variants detected in human resequencing data. These updates include dbNSFP version 4.1, new allele and gene frequencies, and a new integration with Mastermind, a database of genomic literature from Genomenon.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.